VRTX · Vertex Pharmaceuticals Incorporated
504.73
USDUnlock stock Insights
Create a free account to unlock price targets, recommendations, and commentary.
Overview
Market Cap
US$127.93B
PE
29.60
EV/EBITDA
22.2
DIV Yield
0%
Payout Ratio
0%
MQV Rating
4Weak
As at 02/10/2026 04:00:00 PM
Price Chart
Description
- All-Companies
- All-Consensus
- ALL-Recommendations
- HALO 200
- HALO 500
- HALO All
- HALO Balance Sheet
- Hammer Bearish
- Hammer Bullish
Key Fundamentals
EPS 3 yr Growth
19.20%
EBITDA Margin
41.10%
Operating Cashflow
$3,631m
Free Cash Flow Return
18.80%
ROIC
20.40%
Interest Coverage
373.50
Quick Ratio
2.50
Performance
52 weeks range
Low 400.73 - 560.25
Trade Value (12mth)
US$160,367,950.00
1 week
3.51%
1 month
-3.9%
YTD
16.38%
1 year
36.41%
All time high
560.25
Additional Data
Shares Outstanding (Fully Diluted)
255m
HALO Sector
Healthcare
Next Company Report Date
09-Feb-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
Health Scores
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
Mqv
Weak
Garp
Very Weak
Mqv Small
Neutral
Momentum
Price
Strong
Earnings
Very Weak
Growth
Earnings
Weak
Dividends
Very Weak
Quality
Capital Efficiency
Strong
Balance Sheet
Very Strong
Valuation
News & Announcements
| Date | Event |
02 September 26EDG | |
05 August 26EDG | |
05 August 26EDG | |
04 August 26EDG | |
04 August 26EDG |
Key Stakeholders
| Name | Title |
| Amit K. Sachdev | Individual |
| Stuart A. Arbuckle | Individual |
| Ourania Tatsis | Individual |
| Reshma Kewalramani | Individual |
| Ourania Tatsis | Individual |